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Introduction. Dihydrofolate reductase (DHFR) has been used successfully as a drug target in the 
area of anti-bacterial, anti-cancer and anti-malarial therapy. Although this bifunctional enzyme is also a 
potential drug target for treatment of leishmaniasis, there have been no reports on its efficacy against 
Leishmania (Viannia) species.
Materials and methods. The gene encoding the bifunctional DHFR and thymidylate synthase (TS) of 
Le. (V.) braziliensis was isolated and expressed in E. coli. The enzyme was purified and characterized. 
The inhibitory effects of antifolates and four aporphine alkaloids on its activity were evaluated.
Results. The full-length gene consists of a 1560-bp open reading frame encoding a 58 kDa translated 
peptide containing DHFR and TS domains linked together in a single polypeptide chain. The recombinant 
DHFR-TS enzyme revealed Km and Vmax values of 55.35 ± 4.02 μM (mean ± SE) and 0.02 ± 5.34 x 
10-4 μM/min respectively for dihydrofolic acid (H2F). The Le. braziliensis rDHFR-TS have Ki values for 
antimicrobial antifolates in the μM range. Methotrexate (MTX) was a more-potent inhibitor of enzymatic 
activity (Ki = 22.0 μM) than trimethoprim (Ki = 33 μM) and pyrimethamine (Ki = 68 μM). These Ki values 
are significantly lower than those obtained for the aporphine alkaloids.
Conclusion. The results of the study show the inhibitory effect of antifolate drugs on enzymatic activity, 
indicating that Le. braziliensis rDHFR-TS could be a model to studying antifolate compounds as 
potential antiprotozoal drugs.
Keywords: Leishmania braziliensis, tetrahydrofolate dehydrogenase, thymidylate synthase, folic acid 
antagonists.
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Caracterización bioquímica de la enzima bifuncional dihidrofolato reductasa-timidilato sintasa 
de Leishmania (Viannia) y su evaluación como blanco molecular
Introducción. La dihidrofolato reductasa (DHFR) se ha utilizado como blanco molecular en 
tratamientos antibacterianos, anticancerígenos y antipalúdicos. También, actúa como blanco molecular 
en Leishmania; sin embargo, no existen reportes de la enzima bifuncional en especies de Leishmania 
(Viannia).
Materiales y métodos. Se ha aislado y expresado en Escherichia coli el gen que codifica para la enzima 
bifuncional DHFR y la timidilato-sintasa (TS) de Leishmania braziliensis. La enzima recombinante 
se purificó y caracterizó, y se evaluó el efecto inhibitorio de algunos antifolatos, así como de cuatro 
alcaloides aporfínicos.
Resultados. El gen se compone de aproximadamente 1.560 pb y codifica un péptido de 58 kDa que 
contiene los dominios DHFR y TS ligados en una sola cadena polipeptídica. La enzima recombinante 
DHFR-TS, utilizando el dihidrofolato (H2F) como sustrato, presentó valores de Km y Vmax de 55,35 
± 4,02 (media ± el error estándar de la media) y de 0,02 ± 5,34 x 10-4, respectivamente. La enzima 
rDHFR-TS de L. braziliensis presentó valores de Ki para los antifolatos en el rango de micras. El 
metotrexato fue el inhibidor más potente de la actividad enzimática (Ki=22,0 mM) en comparación del 
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trimetoprim (Ki=33 mM) y la pirimetamina (Ki=68 mM). Estos valores de Ki son significativamente más 
bajos en comparación con los obtenidos para los alcaloides aporfínicos.
Conclusión. Los resultados muestran el efecto inhibitorio de los antifolatos sobre la actividad 
enzimática, lo cual indica que la rDHFR-TS de L. braziliensis podría ser un modelo para estudiar 
moléculas antiprotozoarias potenciales.
Palabras clave: Leishmania braziliensis, tetrahidrofolato deshidrogenasa, timidilato sintasa, 
antagonistas del ácido fólico.
doi: http://dx.doi.org/10.7705/biomedica.v33i3.1434
Leishmaniasis is a parasitic disease caused by 
different species of Leishmania and transmitted by 
phlebotomine sand flies of the genus Lutzomyia 
in the Americas and Phlebotomus in the Old 
World. The disease constitutes a severe public 
health problem in at least 98 countries, as well 
as several that are non-endemic but are currently 
experiencing increased numbers of imported 
cases as a consequence of international tourism 
(1-4). An estimated 14 million people are infected 
and about two million new cases occur each year 
(5). In Latin America, Leishmania species of the 
subgenus Viannia are widespread and occur in 
several orders of mammals, including humans. 
The species Le. braziliensis is considered to be the 
main etiological agent of cutaneous leishmaniasis 
(CL) in at least 15 countries of the Americas and is 
also responsible for most mucocutaneous cases of 
the disease (6). In Colombia a second species, Le. 
(V.) panamensis, is also present and sometimes 
involved in mucocutaneous cases (7). 
Control of the disease currently relies primarily on 
chemotherapy and to a lesser extent on vector 
control measures. A limited number of drugs is 
available and each has various shortcomings. 
Traditional antileishmanial systemic agents such 
as antimonials, pentamidine and amphotericin are 
limited by severe toxic side effects, emerging drug 
resistance and their requirement for parenteral 
administration (8-12). Newer agents such as oral 
miltefosine have shown efficacy and tolerability, 
although the efficacy of this compound has not been 
demonstrated for all Leishmania species. There is 
an urgent need to look for new alternatives (11,13). 
One of the first steps in the drug development 
process is the identification of essential molecules 
which can act as potential targets. The genes 
encoding for the enzymes dihydrofolate reductase 
(DHFR) and thymidylate synthase (TS) have 
undergone a fusion event generating a single 
polypeptide but conserving the two functions in 
trypanosomatids (14,15). Dihydrofolate reductase 
(DHFR; EC 1.5.1.3) is an essential enzyme in 
the tetrahydrofolate pathway which catalyzes the 
NADPH-dependent reduction of 7,8-dihydrofolate 
(H2F) to the 5,6,7,8-tetrahydrofolate (H4F) needed 
to maintain intracellular pools of H4F and its 
derivatives; these are essential cofactors in the 
biosynthesis of purines, pyrimidines and several 
amino acids. As a result, it is the target enzyme of 
a group of antifolate drugs, such as methotrexate 
(MTX), trimethoprim, and pyrimethamine, which 
are already in use as anti-tumor and antimicrobial 
agents (15,16). This bifunctional enzyme is 
attractive as a drug target for several reasons; i) 
the metabolic pathway in which it participates is a 
critical route in parasite survival due to its role in 
synthesis of purine and pyrimidine nucleotides; ii) 
as a result of the fusion event, the DHFR and TS 
activities are condensed into a single protein, so 
inhibition of a single polypeptide would block two 
steps in the nucleotide synthesis - this is in contrast 
to the human counterpart, where DHFR and TS 
enzymes occur as two separate monofunctional 
proteins. iii) structural differences between the 
fusion protein DHFR-TS in trypanosomatids and the 
individual polypeptides in humans make this protein 
an attractive target for rational drug design (17).
In the present study a 1.5 Kbp coding for the 
bifunctional DHFR-TS from Le. braziliensis and 
Le. panamensis was amplified and cloned. The 
complete coding sequence (CD) of Le. panamensis 
was sequenced and aligned against the sequence 
annotated in the Le. braziliensis genome (GeneDB). 
The gene encoding the DHFR-TS from Le. braziliensis 
was expressed as recombinant protein in E. coli. 
The enzymatic activity and kinetic parameters of the 
purified Le. braziliensis rDHFR-TS were determined 
using spectrophotometry. Finally, the inhibitory 
activity of four aporphine alkaloids and some 2,4-
diamino-pyrimidine antifolates were evaluated with 
the rDHFR-TS recombinant protein.
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Materials and methods
Amplification of the rDHFR-TS gene
The complete coding sequence of the DHFR-TS 
gene from Le. braziliensis and Le. panamensis 
strains were amplified using DNA isolated from 
promastigotes in a PCR System 9700 thermocycler 
(Applied Biosystems). The genomic DNA was 
prepared using the Wizard DNA extraction kit 
(Promega), following the manufacturer’s instructions. 
DNA from Trypanosoma cruzi was kindly provided 
by the Chagas’ Disease Laboratory of the University 
of Antioquia. The ORF was amplified using the 
sense primer 5´-cgcggatccatgtccagggcagctgcga-3´ 
containing the BamHI site and the antisense primer 
5´-cccaagcttctatacggccatctccatctt-3´ containing the 
HindIII site. The restriction sites included allowed 
directional cloning of the genes in the pQE30 
expression vector (Qiagen). The amplification 
reaction contained 200-300 ng of genomic DNA, 1X 
reaction buffer, 2 mM MgCl2, 0.2 mM of each dNTP 
and 0.05U/μl of Taq DNA polymerase in 25 μl of 
total volume. The PCR cycling condition consisted 
of a single cycle at 95°C for 5 min, followed by 35 
cycles of 94°C for 1 min, primer annealing at 60°C 
for 45 s and extension at 72°C for 2 min. The PCR 
included a final extension cycle at 72°C for 7 min. 
An aliquot of the amplified products was visualized 
by electrophoresis on 1% agarose gel containing 
0.5 μg/ml of ethidium bromide.
Cloning of the DHFR-TS gene
The 1.5 Kbp PCR product was purified from the 
agarose gel and initially cloned into the pGEM-T-
Easy vector (Promega) following the manufacturer’s 
instructions, transformed into DH5α E. coli-
competent cells and plated on LB agar medium 
containing 100 μg/ml of ampicillin. Bacteria clones 
were screened for the presence of the 1.5 Kbp-insert 
by restriction enzyme and/or PCR using the DHFR-
TS specific primers. The insert was subcloned in 
the BamHI/HindIII restriction sites, presented in the 
pQE30 his-tagged expression vector (Qiagen) and 
expressed as a recombinant protein in the E. coli 
M15-pREP4 strain upon induction with isopropyl 
β-D-thiogalactopyranoside (IPTG), as described 
below.
Sequencing of the DHFR-TS gene of Le. 
panamensis
The PCR product of Le. panamensis previously 
cloned in the pGEM-T-Easy vector was sequenced 
by both chains using the primers T7 and SP6 which 
flank the multicloning site. The forward and reverse 
sequences were edited using the Chromas Lite 
program (Technelysium Pty Ltd).
Expression and purification of the recombinant 
DHFR-TS protein
Single colonies of E. coli M15(pREP4) harboring 
the pQE30 construct were grown overnight in 10 
ml of Luria-Bertoni medium with ampicillin (100 μg/
ml) and kanamycin (25 μg/ml) in a thermal shaker. 
Five mL of the overnight culture was used to grow 
up 1 L of bacteria in the same medium under the 
same conditions. The cells were grown at 25ºC with 
shaking until an OD of 0.4-0.6 at A600 was reached. 
Protein expression was induced with IPTG to a 
final concentration of 1 mM and 2mM for 24 h, prior 
to harvesting of cells by centrifugation at 8000×g 
for 10 min at 4°C. Aliquots of 200 μl were taken 
from the culture at 6, 12 and 24 h post-induction to 
evaluate protein expression in a 12% SDS-PAGE 
gel. The cell pellet obtained from 1 L-culture was 
re-suspended in binding buffer (10 mM imidazole, 
300 mM NaCl, and 50 mM NaH2PO4, pH 8.0) and 
lysed by sonication at 2500 db. After centrifugation 
at 18 000 g at 4°C for 20 min, the supernatant was 
collected and loaded onto a precharged nickel 
affinity column (Ni-NTA resin). The column was 
washed once with binding buffer (300 mM NaCl, 
and 50 mM NaH2PO4, pH 8.0) and once with 20 
mM imidazole. The recombinant protein was eluted 
under native conditions with 250 mM imidazole. 
Each step of the purification procedure was 
monitored on 12% SDS-PAGE gels and stained 
with Coomassie blue. Protein concentration was 
determined by (18) using a protein assay kit from 
Bio-Rad Laboratories (Hercules, Calif.). The pH 
was adjusted to 6.0 to stabilize enzyme activity. 
Enzyme activity assay and kinetic evaluation
The activity of the recombinant enzyme rDHFR-TS 
of Le. braziliensis was determined spectrophoto-
metrically (CaryBio 50) by monitoring the decrease of 
NADPH absorbance at 340 nm and 28°C. The assay 
was developed based on the basic DHFR assay 
described by Reche et al. (19) with minor modifications. 
All procedures were conducted in sealed PMMA 
cuvettes. The standard reaction mix (1.0 ml) consisted 
of 25 μM of the rDHFR-TS in a buffer solution (pH 6.0), 
containing NADPH 100 μM, H2F 50 μM and BSA 1 
mg/ml. The Michaelis-Menten constants (Km) were 
determined at constant concentration of NADPH 
and varying the H2F concentration in a range 25 
to 100 μM. The kinetic data were analyzed by a 
nonlinear least squares fit using the software 
GraphPadPrism® Version 4.00 for Windows. 
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Assay for sensitivity of DHFR-TS to antifolates 
and aporphine compounds
Four aporphine alkaloids from Rollinia pittieri and 
Pseudomalmea boyacana (Annonaceae) (20) were 
evaluated as potential inhibitors of the rDHFR-TS 
enzyme (Table 1). The antifolates methrotexate 
(MTX), trimethoprim and pyrimethamine were 
included as inhibition controls. Inhibition experiments 
were conducted at constant concentrations of 
NADPH (100 μM) and various H2F concentrations 
ranging from 25 to 100 μM, in the presence of 
different concentrations of the inhibitors. For 
determinations of the IC50 values, initial velocities 
were measured at five or more concentrations, 
revealing <10% to >100% of the control activity. 
Assays were started by the addition of dihydrofolic 
acid after pre-incubation of the enzyme with 
each inhibitor dissolved in assay buffer. Inhibition 
constants (Ki) of the compounds were calculated 
from a nonlinear least square equation for 
competitive or noncompetitive inhibition. The type 
of inhibition by the compounds against rDHFR-TS 
was analyzed by standard double reciprocal plots. 
Results
PCR amplification, cloning and sequencing of 
the ORF of the DHFR-TS gene
The complete ORF of the DHFR-TS enzyme was 
amplified in two species of the Viannia subgenus 
as well as in T. cruzi. The reaction yielded a PCR 
product of approximately 1.5 Kbp (Fig. 1). The 
amplified products of Le. panamensis were purified 
and cloned directionally in the BamHI and HindIII 
restriction site of the pQE30 expression vector (data 
not shown). The Le. panamensis DHFR-TS sequence 
of the UA140 Colombian strain (the nucleotide 
sequence has been assigned the accession number 
KC846139 by GenBank) was aligned against the 
Le. braziliensis (LbrM.06.0830), sequence obtained 
from geneDB, Sanger Institute, and DHFR-TS 
sequences of Le. major (XM_001680805.1), Le. 
infantum (FR796438.1) and Le. amazonensis 
(X51735.1), which were downloaded from GenBank. 
A high conservation at nucleotide level was observed 
among species, ranging from 85-98% depending on 
the species.
Induction and purification of the recombinant 
protein
Induction of the expression with 1 and 2 mM of 
IPTG resulted in a specific protein band of the 
expected size (58 kDa) either at 12 or 24 h post-
induction (Fig. 2a). Purification was performed by 
nickel-nitrylotriacetic acid (Ni-NTA) metal-affinity 
chromatography. The protein displayed a 58-kDa 
band on 12% SDS-PAGE (figure 2b) which is in 
agreement with the expected size from the amino 
acid sequence (21). The purified protein was stable 
at pH 6.0, over a period of 1 month when stored at 
-20°C. A good amount of the rDHFR-TS protein was 
obtained after purification on the Ni-NTA resin.
Figure 1. Amplification of DHFR-TS in DNA purified from 
Le. braziliensis, Le. panamensis and T. cruzi. A fragment of 
approximately 1.5 kb was amplified. M: Molecular marker; line 
1, Le. panamensis UA140; line 2, Le. braziliensis M2903; line 3, 
Le. panamensis, UA1741 and line 4, Le. panamensis UA 1720, 
line 5, T. cruzi and line 6, Negative control. The samples were 
visualized on 1.0% agarose gel containing 0.5 μg/ml ethidium 
bromide. 
Table 1. Inhibitor efficacies against rDHFR-TS from Leishmania braziliensis and kinetics parameters of classical antifolates and 
aporphine alkaloids
Compound tested CI50 (μM) Ki (mM)a Kinetics parametersa Type of inhibition
   Km (mM) Vmax (μM/min) 
Methotrexate 1.50 0.022 0.178 0.0163 Competitive
Trimethoprim 152.33 0.033 0.137 0.0163 Competitive
Pyrimethamine 12.51 0.068 0.096 0.0165 Competitive
Isomoschatoline 2.91 x 107 0.717 0.132 0.0163 Competitive
Atherospermidine 3.00 x 104 0.748 0.129 0.0164 Competitive
Melosmine 2.90 x 105 1.260 0.099 0.0161 Competitive
Liriodenine 6.13 x 108 2.615 0.076 0.0165 Competitive
a Data obtained at 28°C.
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Enzymatic activity and kinetics parameters of 
the recombinant enzyme
To evaluate the enzymatic activity, 25 μM of rDHFR-
TS was added to the reaction mixture and changes 
in absorbance at 340 nm were monitored. A fast 
drop in the absorbance was observed decreasing 
from 0.34 to 0.15 (Fig. 3), providing evidence 
that rDHFR-TS catalyzes the NADPH-dependent 
reduction of H2F to H4F at 28ºC in 60 min. The time 
and temperature to perform the assays was 30 
min and 28ºC; under these conditions the cofactor 
NADPH retains its initial absorption spectrum. 
As control, an enzyme-free reaction mixture was 
evaluated and no changes in absorbance values 
were observed. Based on this enzyme activity, we 
proceeded to determine the steady-state kinetic 
parameters for the enzyme substrate and the 
cofactor (H2F and NADPH). The Km and Vmax values 
of the rDHFR-TS from Le. braziliensis measured in 
the H2F reaction were 55.35 ± 4.02 μM and 0.02 
± 5.34 x 10-4 μM/min, respectively. One unit of 
the enzyme was defined as the amount required 
to catalyze the generation of 1 μM of product per 
minute, equivalent to 4.30 x 10-4. The specific 
activity was determined to be 0.0087 U/mg (data 
not shown).
Evaluation of enzyme inhibition
The kinetics of enzyme inhibition by three 2,4-
diamino-pyrimidine classical antifolates (MTX, 
trimethoprim and pyrimethamine) as well as four 
aporphine alkaloids (liriodenine, melosmine, 
atherospermidine and isomoschatoline) were 
evaluated as inhibitors of the purified rDHFR-TS 
from Le. braziliensis. H2F, the substrate for the 
DHFR enzyme, shares structural similarities in its 
chemical structure with the classical antifolates via 
their common aminopyrimidine ring (Fig. 4). We 
would therefore expect these drugs to compete 
for the active site in the DHFR domain, potentially 
leading to an inhibitory effect. To examine this 
possibility, the kinetic results of enzyme inhibition 
of the compounds were transformed using a 
Lineweaver Burk plot. Indeed, MTX, pyrimethamine, 
and trimethoprim all inhibited the enzymatic activity 
in a dose-dependent manner, MTX being the best 
Figure 3. Kinetic course of change in NADPH electronic 
absorption spectrum in the presence of H2F. The assays 
contained 25 μM of rDHFR-TS in a buffer solution (pH 6.0), 
NADPH 100 μM, H2F 50 μM and BSA 1 mg/ ml. Electronic 
absorption spectra was obtained at 28°C for 60 minutes with 4 
minute of intervals between each measurement.
Figure 2. Evaluation of the rDHFR-TS protein expression in 12% SDS-PAGE after induction of the E. coli cells with IPTG (Panel A) 
and purification by Ni-NTA (Panel B). Both gels were stained with Coomassie brilliant blue. The samples loaded and shown in panel 
A correspond to: M, molecular weight; line 1, non-induced cells for 12 h; line 2, cells induced with 1 mM of IPTG for 12 h; line 3, cells 
induced with 2 mM of IPTG for 12 h; line 4, non-induced cells for 24 h; line 5, cells induced with 1 mM of IPTG for 24 h and line 6, 
cells induced with 2 mM of IPTG for 24 h. Samples loaded in gel showed in panel B correspond to: line 1, Flow through, line 2 and 3: 
fraction collected after two washing steps and samples from line 4 to 10 are different eluted fractions from the Ni-NTA column. 
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inhibitor (IC50 = 1.5 μM) (Fig. 5). The Ki values of 
the classical antifolates were in the micromolar 
range, whereas the aporphine compounds 
inhibited the target enzyme at the mM level (Table 
1). In addition, the Lineweaver Burk plots indicate 
that all the evaluated antifolate compounds are 
competitive inhibitors for the enzyme. 
Discussion
DHFR is a key enzyme in folate metabolism, 
linked to the production of thymidine (12). 
In several species of protozoa, the catalytic 
activities for the enzymes DHFR and TS reside 
on a single polypeptide chain, constituting a 
bifunctional DHFR-TS enzyme (14,15). The ORF 
of the DHFR-TS has been amplified, cloned and 
sequenced; the sequences showed a high degree 
of conservation, both at nucleotide (96%) and 
protein (90%) level. The bifunctional enzyme has 
been thus considered as a potential drug target 
(12,15). Nevertheless, there are no reports on 
the bifunctional enzyme on Le. (V.) species. A few 
inhibition studies using different compounds have 
been conducted on a few Leishmania species, 
including Le. major and Le. mexicana, as well as 
T. brucei and T. cruzi (22-30). It was considered 
interesting to evaluate the activity of the rDHFR-
TS in the presence of classical antifolates. The 
rDHFR-TS enzyme purified in this study showed 
good activity, some of the compounds evaluated 
being inhibitors of the recombinant enzyme. In 
this sense, MTX was the best inhibitor (IC50 = 1.50 
μM; Ki = 22.0 μM). In previous studies, MTX has 
been shown to be a potent inhibitor of Le. major 
and T. cruzi DHFR-TS and also to show activity 
against promastigotes of different Leishmania 
species (24,26). The classical anti-microbial DHFR 
inhibitors trimethoprim (IC50 = 152.33 μM; Ki = 
33 μM) and pyrimethamine (IC50 = 12.51 μM; Ki 
= 68 μM) were, in general, not very selective for 
the analogous leishmanial enzyme compared to 
MTX. Trimethoprim and pyrimethamine have been 
Figure 4. Chemical structure of the DHFR substrate, DHF (a), the antifolate drugs MTX (b), pyrimethamine (c), trimethoprim (d), and 
the aporphine alkaloids liriodenine (e), melosmine (f), atherospermidine (g) and isomoschatoline (h). 
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reported as moderately selective for Le. major 
and T. cruzi DHFR (25,31). The aminopteridine 
ring of MTX and the aminopyrimidine ring of 
pyrimethamine and trimethoprim closely resemble 
those of the substrate, H2F (Fig. 4). We would thus 
expect these antifolate compounds to compete with 
the substrate by binding to amino acid residues 
in the hydrophobic pocket of the active site of 
the rDHFR-TS enzyme, producing the observed 
inhibitory effect. MTX is a particularly potent inhibitor 
compared to pyrimethamine and trimethoprim 
because the molecule, by having a pteridine ring 
and glutamic acid, is an only slightly modified 
version of DHF, the normal substrate of DHFR. 
It thus competes effectively with the substrate for 
the rDHFR-TS active site. The results obtained 
indicate that the structural requirements for DHFR 
inhibition are critically important in determining the 
possible inhibitory activity of different compounds 
tested and in the design of selective antifolates for 
parasite chemotherapy.
In contrast, no studies have addressed the 
inhibitory effects of aporphine alkaloids on 
rDHFR-TS from Leishmania. Thus, we were 
also interested in evaluating these non-classical 
analogues as inhibitors of Le. braziliensis DHFR-
TS. The aporphine alkaloids were weak inhibitors 
of enzymatic activity, as indicated by their high Ki 
values. However, our kinetics studies showed that 
the most active compound was isomoschatoline 
(Ki = 0.72 mM), followed by atherospermidine (Ki 
= 0.75 mM). The aporphine alkaloid showed some 
degree of activity when it was assayed against 
Le. braziliensis promastigotes (M2903) with IC50s 
of less than 23 μg/ml (32). This indicates that 
its possible mode of action is not related to the 
inhibition of DHFR. Folate analogues that inhibit 
DHFR generally contain 2,4-diamino substitution 
in the pyrimidine ring, typified by MTX. In contrast, 
folate analogues that inhibit TS generally contain an 
oxo- or methyl-oxo substitution as in Pemetrexed 
and Raltiterxed, both already in clinical use (33). 
The aporphine alkaloids evaluated present some 
of the structural requirements necessary to inhibit 
TS, although further studies are required to check 
its activity. In addition, it should be noted that 
the aporphine and oxoaporphine alkaloids are 
isoquinoline compounds known to have various 
pharmacological properties, including antiparasitic 
activity. Another mode of action could thus be 
involved (34). The mechanism of action of aporphine 
alkaloids seems to be related, at least in part, to the 
inhibition of topoisomerase II by DNA intercalation 
or minor groove binding (35,36). The identification 
of liriodenine as a strong topoisomerase II catalytic 
inhibitor and a topoisomerase II poison has led 
to the search for other topoisomerase II inhibitors 
among the aporphine alkaloids (35). 
In conclusion, this study reports the first isolation, 
cloning, and expression of the Le. braziliensis 
DHFR-TS gene, providing a corresponding purified 
rDHFR-TS enzyme of approximately 58 kDa that is 
catalytically active. Additionally, the results of the 
study show the inhibitory effect of antifolate drugs 
on enzymatic activity, indicating that Le. braziliensis 
rDHFR-TS could be a model for studying antifolate 
compounds as potential antiprotozoal drugs. The 
following sections will elaborate on the overall 
structure of the enzymes, the interactions with 
the substrate and inhibitors and future structure-
based drug design goals. One aspect to consider 
is the several potential resistance mechanisms to 
DHFR that have been discovered including over-
expression of the enzymes DHFR-TS and pteridine 
reductase 1 (PTR1) (37,38). The enzyme PTR1 is 
predominantly involved in reduction of biopterin to 
dihydrobiopterin and tetrahydrobiopterin but also 
capable of reducing dihydrofolate to tetrahydrofolate 
Figure 5. Inhibition curves of MTX, pyrimethamine 
and trimethoprim against rDHFR-TS enzyme activity. 
Triplicate inhibition curves were generated for 
each drug and mean standard errors of the means 
were calculated. The curves were fitted using the 
calculated mean values for each concentration by 
using the software GraphPadPrism®, version 4.00, 
for Windows. 
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(38). Hence, a combined strategy to target both 
DHFR and PTR1 will be more effective as a true 
antileishmanial drug (12). 
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